Global Liver Institute
GLOBAL LIVER INSTITUTE
Launched in 2017, the GLI NASH Council seeks to shine a spotlight and coalesce an expanded set of stakeholders, in addition to hepatology, around the urgency of developing mechanisms for quantifying and addressing the epidemic of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the U.S. and abroad. The NASH Council convenes twice per calendar year and may create workgroups to advance and develop specific concepts.
International NASH Day
International NASH Day (#NASHDay) is a public education campaign launched in June 2018 to raise visibility and urgency around fatty liver disease and its more advanced form, nonalcoholic steatohepatitis (NASH), which affects more than 115 million people around the world.
Held annually on the second Thursday of June, NASH Day convenes physicians, advocates, and other experts to share the latest insights on how to prevent, diagnose, and manage fatty liver disease. An informed worldwide community is essential to reduce the global prevalence of fatty liver disease, which can advance dangerously if left undetected and unacknowledged. Patients, caregivers, medical providers, policymakers, and all other advocates will learn actionable ways to support patients already diagnosed with NASH and to seek methods of risk reduction.
2021 NASH Diagnostics Forum
GLI, Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore), and Integritas Communications (Integritas) have received an educational grant from Pfizer, Inc., to execute the 2021 NASH Diagnostics ForumTM. The initiative, titled “A Critical Appraisal of Noninvasive Technologies in NASH: Informing the Future of NASH Diagnosis and Assessment,” will convene a multidisciplinary panel of experts to conduct a comprehensive analysis of available data on noninvasive biomarkers and tools for diagnosis, prognosis, and monitoring of NASH. The grant will also support dissemination of the Forum’s findings to the broader medical community via multiple media.
The council joined 150+ drug developers from 120+ organizations at this focused discussion and networking forum and gain actionable insights to accelerate the development of NASH therapeutic pipelines.
The Liver Forum
The Liver Forum is an initiative of the Forum for Collaborative Research, part of the University of California, Berkeley School of Public Health. The Liver Forum was launched in 2014 in response to The Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic Fatty Liver Disease (NAFLD) meeting sponsored in 2013 by the U.S. Food and Drug Administration (FDA) and the American Association for the Study of Liver Disease (AASLD).
The Liver Forum aims to advance the regulatory sciences for the treatment of nonalcoholic steatohepatitis and liver fibrosis by providing an independent and neutral venue for ongoing multi-stakeholder dialogue to identify and address gaps in the field. Neutrality and objectivity is ensured through representation and active engagement of scientific experts from all stakeholder groups, including academia, industry, patient community and regulatory agencies.
GLI President and CEO Donna R. Cryer, JD is included in this expert group of stakeholders on the steering committee as a community representative.
US NASH Action Plan
GLI and the GLI NASH Council released the U.S. NASH Action Plan to comprehensively address NASH and its impact on patients and families, public health, and the economy.
The Language of NASH: A Narrative Guide to Communication on NASH
To increase awareness of fatty liver disease, we all need to speak the same language. This framework for communication about NAFLD and NASH will help physicians, patients, caregivers, families, and advocates use the same wording to send a clear message: it’s time to increase awareness, diagnosis and treatment options for NASH.
The Global Liver Institute NASH Council brings together representatives from not-for-profit, for-profit, and governmental entities capable of and committed to addressing the challenges of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on individuals, communities, companies, and society.